Date: 2014-11-10
Type of information: Establishment of a new subsidiary in the EU
Compound:
Company: Eisai (Japan)
Therapeutic area: Cancer - Oncology - Neurological diseases
Type agreement: expansion of a subsidiary
Action mechanism:
Disease:
Details: * On November 10, 2014, Eisai EMEA (Europe, Middle East, Africa, Russia and Oceania) announced the official expansion of its Belgian operation to include neuroscience alongside its oncology capabilities. The Eisai Belgium office was opened in September 2013 and is based in Brussels. The neuroscience business unit will market Fycompa® (perampanel), launched in Belgium in August 2014, indicated for the adjunctive treatment of partial onset seizures, with or without secondarily generalised seizures, in patients with epilepsy aged 12 years and older. In addition the neuroscience business unit is responsible for Inovelon® (rufinamide), commercially available in Belgium since March 2012 and indicated as an adjunctive therapy in the treatment of epileptic seizures associated with Lennox-Gastaut syndrome (LGS) in patients 4 years and older.
Financial terms:
Latest news:
